Intelligence · Clinical Development
Pipeline search results
Programs matching “trastuzumab deruxtecan” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 13 pipeline programs matching "trastuzumab deruxtecan" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Trastuzumab Deruxtecan
Daiichi Sankyo
Ovarian Cancer
1 trial -
Trastuzumab Deruxtecan
AstraZeneca
Breast Neoplasms
1 trial -
Trastuzumab Deruxtecan
AstraZeneca
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
Trastuzumab Deruxtecan
Daiichi Sankyo
Gastric Cancer
1 trial -
Trastuzumab Deruxtecan
Daiichi Sankyo
Non-small Cell Lung Cancer
1 trial -
Trastuzumab deruxtecan
AstraZeneca
Breast Cancer; HER2-positive; Metastatic
1 trial -
Trastuzumab deruxtecan
AstraZeneca
Advanced or Metastatic Breast Cancer
1 trial -
2023/3668
The George Institute
Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.
1 trial -
TRASTUZUMAB DERUXTECAN
Fondazione Telethon ETS
metastatic HER2-positive breast cancer patients
1 trial -
TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN
Ningbo Cancer Hospital
Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.
1 trial -
Trastuzumab deruxtecan
AstraZeneca
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
1 trial -
Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.
Daiichi Sankyo
Advanced Solid Tumor
1 trial -
Trastuzumab Deruxtecan
Daiichi Sankyo
Recurrent or Metastatic Solid Tumors
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.